Mice lacking c-fos develop osteopetrosis due to a block in osteoclast differentiation. Carboxy-terminal phosphorylation of Fos on serine 374 by ERK1/2 and serine 362 by RSK1/2 regulates Fos stability and transactivation potential in vitro. To assess the physiological relevance of Fos phosphorylation in vivo, serine 362 and/or serine 374 was replaced by alanine (Fos362A, Fos374A and FosAA) or by phospho-mimetic aspartic acid (FosDD). Homozygous mutants were healthy and skeletogenesis was largely unaffected. Fos C-terminal phosphorylation, predominantly on serine 374, was found important for osteoclast differentiation in vitro and affected lipopolysaccharide (LPS)-induced cytokine response in vitro and in vivo. Importantly, skin papilloma development was delayed in FosAA, Fos362A and Rsk2-deficient mice, accelerated in FosDD mice and unaffected in Fos374A mutants. Furthermore, the related Fos protein and putative RSK2 target Fra1 failed to substitute for Fos in papilloma development. This indicates that phosphorylation of serines 362 and 374 exerts context-dependent roles in modulating Fos activity in vivo. Inhibition of Fos Cterminal phosphorylation on serine 362 by targeting RSK2 might be of therapeutic relevance for skin tumours.
Introduction
The dimeric AP-1 transcription factor is central to many biological processes. Fos (Fos, FosB, Fra1 and Fra2) and Jun (Jun, JunB and JunD) proteins as well as proteins belonging to the ATF and MAF families, associate following strict interaction rules and bind to the regulatory regions of target genes. AP-1 recognizes in a dimer-dependent manner, regulatory sequences on the DNA resembling the canonical 12-O-tetradecanoylphorbol-13-acetate (TRE) or cyclic adenosine monophosphate (CRE) response elements. Binding of different AP-1 dimers to an identical sequence can result in different transcriptional responses depending on the dimer composition (Eferl and Wagner, 2003) . The importance of AP-1 in various physiological and pathological processes in the context of the whole organism has been unequivocally demonstrated using gene-targeting approaches in mice, wherein individual or multiple genes encoding AP-1-forming proteins have been inactivated, ectopically expressed or replaced one by another (Eferl and Wagner, 2003; Hess et al., 2004) .
AP-1 responds to a plethora of stimuli and is regulated at multiple levels. In particular, the regulation of the immediate early gene c-fos and its protein product Fos has been extensively studied and serves as paradigm for the tight, dynamic and multi-level regulation of stress and growth factors responses (Nakakuki et al., 2010) . Fos is expressed below detection levels in cultured cells and in most cells of the organism. The induction of c-fos mRNA in response to growth factors predominantly relies on the extracellular signal-regulated kinases 1/2 (ERK1/2) cascade. The newly expressed Fos protein is unstable and Fos only accumulates when phosphorylated. Although biochemical studies have allowed the mapping of multiple putative phosphorylation sites in the Fos protein, few sites have been functionally validated and the identity of the kinases phosphorylating Fos is not fully established. Nevertheless, numerous reports have shown that in cultured cells serinethreonines kinases such as ERK1/2, ERK5, IKKb, PKA, RSK and a undefined Fos-related kinase can phosphorylate and alter Fos stability by targeting at least six different residues, mostly in the C-terminal part of the protein (Chen et al., 1993; Deng and Karin, 1994; Sasaki et al., 2006; Koga et al., 2009) . Several studies demonstrated how ERK1/2 and RSK1/2 cooperate to stabilize the Fos protein and provided evidence for an important role of Fos C-terminal phosphorylation in the regulation of Fos transcriptional activity. Two residues, serine 374 and serine 362 located at the C-terminus of Fos, and largely conserved among the Fos proteins, are phosphorylated by ERK1/2 and the ERK-dependent kinase RSK1/2, respectively. In addition to increasing the stability of newly synthesized Fos, phosphorylation of serines 362 and 374 enhances the phosphorylation of two adjacent sites, Thr325 and Thr331. Thus, it was proposed that the phosphorylation of serines 362 and 374 serves to 'prime' Fos for subsequent phosphorylation (Chen et al., 1993; Murphy et al., 2002; Murphy and Blenis, 2006 ). An increase in Fos stability results in greater contribution of Fos to the pool of AP-1 dimers, enhanced promoter occupancy and increased Fos transactivating activity on Fos/AP-1-target genes. On the other hand, early reports indicated that the priming-phosphorylation sites modulate the repressive function exerted by Fos on its own promoter and on those of other early growth response genes (Gius et al., 1990; Ofir et al., 1990) . Finally, although dephosphorylating Fos in vitro leads to rapid protein destabilization, replacing the priming-phosphorylation sites by either non-phosphorylatable or phospho-mimetic residues appear to differentially affect the stability and the transforming activity of Fos, when overexpressed in cultured cells (Tratner et al., 1992; Okazaki and Sagata, 1995; Chen et al., 1996; Murphy et al., 2002; Monje et al., 2003) . These observations indicate that stabilization of Fos is very likely not the unique function of Fos C-terminal phosphorylation and that it might have a target-and signal-dependent role in modulating Fos transcriptional potential.
Although these studies support the fact that Fos C-terminal phosphorylation has an important role, little is known about the physiological function of Fos phosphorylation in the context of the whole organism, in particular in tissues and cell types, wherein Fos is essential such as bone-resorbing osteoclasts (Wang et al., 1992; Grigoriadis et al., 1994) . We have recently demonstrated that Fos phosphorylation by RSK2 is essential for the development of Fos-induced osteosarcomas . However, mice lacking Rsk2 displayed normal osteoclast differentiation and it was postulated that this could be due to RSK2-independent residual serine 362 phosphorylation .
To address the function of Fos C-terminal phosphorylation in vivo, we generated knock-in mice with the Fos-priming phosphorylation sites, serine 362 and serine 374, substituted by alanines either single or in combination (Fos362A, Fos374A and FosAA) or by phosphomimetic aspartic acids (FosDD) within the endogenous Fos protein. Homozygous Fos phosphorylation mutants were viable, indistinguishable from wild-type and bone development was largely unaffected. However, Fos-phosphorylation mutant cells and mice exhibited context-dependent and serine-specific alterations in their responses to different stimuli.
Results

Generation of Fos phosphorylation knock-in mice
We generated knock-in mice harbouring mutant alleles of Fos with serine 362 and serine 374 mutated to alanines (Fos362A, Fos374A and FosAA) or to phospho-mimetic aspartic acids (FosDD). The desired substitutions were obtained by site-directed mutagenesis using as a template the previously described floxed c-fos-targeting construct (Fleischmann et al., 2003a) (Figure 1a ). Each mutant allele was introduced in the genome of embryonic stem cells by homologous recombination. The neomycin resistance cassette was removed in vivo and the resulting phospho-knock-in heterozygous intercrossed. Correct targeting was confirmed by Southern blot and DNA sequencing (Figure 1b , Supplementary Figure 1A and data not shown). Immunohistological analyses of brain sections of kainate-injected FosAA homozygous mutants (hereafter FosAA) indicated that, although Fos protein expression was readily detected 3 h after injection, no signal for serine 362-phosphorylated Fos could be observed in mutant mice when compared with their wild-type littermates (Supplementary Figure 1B) . Furthermore, immunoblot analyses of serum-stimulated fibroblasts indicated that, although Fos was induced at comparable levels in wild-type and FosAA cells, phosphorylation of Fos at serine 362 was undetectable in FosAA extracts (Figure 1c ). On the other hand and consistent with previous reports (Okazaki and Sagata, 1995; Ferrara et al., 2003; Pellegrino and Stork, 2006) , replacement of the two serines by aspartic acids to mimic Fos-priming phosphorylation resulted in higher amounts of Fos protein in serum-stimulated fibroblasts (Figure 1d ). The c-fos mRNA expression is repressed by the Fos protein and modulated by C-terminal phosphorylation (Sassone-Corsi et al., 1988; Gius et al., 1990; Ofir et al., 1990) . Consistently, the induction of c-fos mRNA reached a higher level in FosAA fibroblasts (Figure 1e ), whereas it appeared reduced in FosDD cells (Figure 1f ). Similarly altered serum-response profile was observed for the early growth response gene egr1 (data not shown), which is also trans-repressed by Fos (Gius et al., 1990) , whereas mRNA induction of canonical AP-1 targets such as fra1, mmp10 and mmp13 was not significantly altered (data not shown).
Targeted disruption of Fos results in reduced size and viability at birth and pleiotropic effects in the surviving pups (Wang et al., 1992; Grigoriadis et al., 1994) . In contrast, homozygous FosAA, FosDD, Fos362 and Fos374A mutants were obtained at Mendelian frequency and were indistinguishable from their wild-type or heterozygous littermates (data not shown). Adult mice of both sexes were healthy and fertile. Furthermore, mice with reduced levels of Fos362A, 374A and FosAA transcripts, obtained by intercrosses with Fos-deficient mice, were also obtained at the expected frequency and appeared healthy (data not shown). These data indicate that impairing Fos C-terminal phosphorylation does not affect mouse development.
Fos phosphorylation does not affect bone homeostasis in vivo Histomorphometric analyses revealed a modest but significant increase in bone volume fraction in 4, 12
In vivo functions of Fos phosphorylation L Bakiri et al and 25-week-old FosAA mice (Figure 2a ). Increased trabecular thickness was also observed at 12 weeks of age, whereas trabecular number and spacing were not affected ( Figure 2a and data not shown). No change in volumetric bone and tissue mineral density could be detected by micro-computed tomography (Figure 2b and Supplementary Figure 2A) . FosAA mutant bones displayed decreased osteoclast numbers per bone perimeter, which was only statistically significant in 4-week-old mice (Figure 2c ). Bone resorption, as measured by serum carboxy-terminal collagen or deoxypyridinoline crosslinks was unchanged in 4, 12 and 25-week-old FosAA mice (Figure 2d and data not shown). Indirect blood markers for bone homeostasis such as alkaline phosphatase, osteocalcin, calcium and phosphate were unaltered (Supplementary Figures 2C, D and E) . Fos knock-out mice display reduced periosteal osteoblasts numbers and Fos-deficient primary osteoblasts proliferate slower (Fu et al., 2005) . In FosAA tibiae, osteoblast numbers were comparable to wild-type (data Finally, serum levels of the osteoclast differentiation factor receptor activator of NF-kB ligand and its decoy receptor OPG were unaltered in all mutant mice (Supplementary Figure 2E) .
These data indicate that Fos C-terminal phosphorylation marginally affects osteoclast numbers and fractional bone volume, but does not lead to any detectable change in bone mineralization or resorption in vivo under physiological conditions. 
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Fos phosphorylation modulates osteoclast differentiation in vitro To further investigate the effects of Fos phosphorylation on osteoclast biology, bone marrow hematopoietic progenitors were isolated from the different phosphoFos mutant mice and differentiated into osteoclasts in vitro. Staining for tartrate-resistant acid phosphatase (TRAP), a marker for osteoclasts revealed that differentiation was delayed in FosAA cultures, with smaller and less numerous multinucleated TRAP-positive cells (Figure 3a) . Expression of trap and other osteoclast markers, such as cathK, mmp9, ctr and ca2 was reduced in FosAA cultures (Figure 3a and data not shown). Interestingly, although c-fos expression appeared unchanged, the expression of nfatc-1, a downstream target of Fos essential for osteoclastogenesis, was significantly reduced in FosAA cultures (Figure 3a) . When in vitro osteoclast differentiation was assessed using FosDD bone marrow hematopoietic progenitors, osteoclast differentiation appeared accelerated, with larger and more numerous multinucleated FosDD TRAP-positive cells (Figure 3b ). Nfatc-1 and osteoclast marker genes expression was increased, whereas c-fos mRNA expression was unaffected (Figure 3b and data not shown).
Analysing individual serine mutants (Fos362A and Fos374A) indicated that serine 374 phosphorylation is likely to be the major contributor to the observed effects in double mutant mice. As shown in Figure 3c , osteoclast differentiation was not affected in Fos362A In vivo functions of Fos phosphorylation L Bakiri et al bone marrow cultures and mmp9 was the only osteoclast marker and AP-1 target gene whose expression was consistently reduced. This result is in line with our previous findings wherein decreasing Fos phosphorylation on serine 362 by inactivating its putative kinase Rsk2 had no effect on osteoclastogenesis . However, replacement of Fos serine 374 by an alanine did not affect mmp9 expression, but significantly reduced osteoclast formation (Figure 3d ). We next assessed whether the differentiation defects of FosAA, FosDD and Fos374A bone marrow precursors could be rescued by co-culture with osteoblasts of different genotypes. As shown in Figures 3e and f , phospho-mutant osteoblasts from the three genotypes had the same potential to support osteoclastogenesis of wild-type bone marrow. Furthermore, although co-culture with osteoblasts largely reverted osteoclastogenesis from FosDD and Fos374A progenitors to control levels, osteoclast formation from FosAA bone marrow progenitors remained impaired as assessed by TRAP-positive cell numbers (Figure 3e ) and osteoclast marker gene expression (Figure 3f and data not shown).
These data indicate that C-terminal phosphorylation of Fos, predominantly on serine 374, positively affects osteoclast differentiation and that decreased osteoclast numbers observed in the bones of FosAA mice is cellautonomous, but likely not sufficient to translate into noticeable changes in bone resorptive activity in vivo.
Fos phosphorylation affects lipopolysaccharide (LPS)-induced cytokine response
Macrophages and osteoclasts are derived from the same myeloid precursors. Macrophages and mice lacking Fos display altered cytokine production in response to LPS (Ray et al., 2006) . We therefore explored the contribution of Fos phosphorylation on serines 362 and 374 to LPS-induced cytokine response using bone marrow derived-macrophages from Fos phospho mutant mice. Mice with specific deletion of c-fos in the monocyte/ macrophage lineage (c-fos f/f ; LysMCre, hereafter referred to as Fos cKO) were included for comparison.
Tumor necrosis factor-a (TNFa) and interleukin-6 (IL-6) production were increased in culture supernatants of FosAA, Fos362A, Fos374A and Fos cKO macrophages stimulated with 1ng/ml LPS (Figures 4a and b) , whereas levels of the anti-inflammatory cytokine IL-10 were decreased (Figure 4c ). With respect to individual serines, the differences were more consistent when using Fos374A than Fos362A mutant cells, indicating that serine 374A could have a predominant role. Interestingly, the production of these cytokines was not altered in FosDD macrophages, but TNFa and IL-6 were significantly decreased when using a lower dose of LPS (0.1 ng/ml, Supplementary Figure 4) . These data indicate that C-terminal phosphorylation modulates Fos effects on LPS-mediated cytokine production in cultured macrophages in a dose-and cytokine-dependent manner. 
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We next investigated LPS-induced cytokine response in vivo. Serum TNFa levels were significantly higher in LPS-injected FosAA mice, whereas the opposite was observed in FosDD mice (Figure 4d ). In addition, a decrease in IL-6 and IL-10 was observed in FosDD mutants (Figures 4e and f) . Differences in serum cytokines were not prominent in single-serine mutants. Consistent with previous reports (Ray et al., 2006) , deletion of c-fos in the monocyte/macrophage lineage resulted in hyper-induction of TNFa and IL-6 (Figures 4d  and e) . However, serum IL-10 was also increased in Fos cKO mice (Figure 4f) , indicating that the effect of Fos deletion on IL-10 production is cell-context dependent.
Fos phosphorylation on serine 362 but not on serine 374 is required for skin tumourigenesis We next asked whether Fos C-terminal phosphorylation could also be important in tumour development where Fos expression is required. Fos-deficient mice fail to undergo malignant progression of skin tumours (Saez et al., 1995) . Furthermore, tumour volume was significantly reduced when c-fos was specifically deleted in the epidermis of papilloma-prone K5-SOS-F mice (EF Wagner, unpublished; Durchdewald et al., 2008) .
Papilloma-prone K5-SOS-F transgenic mice expressing a dominant form of Son of Sevenless in basal keratinocytes (Sibilia et al., 2000) were crossed to FosAA mutant mice and Fos expression and phosphorylation were analysed by immunohistochemistry. Fos expression and phosphorylation on serine 362 was readily detectable in the hyperplasic lesions induced by K5-SOS-F in both wild-type and FosAA backgrounds, with Fos phosphorylation restricted to the K5-SOS-F mice harbouring wild-type c-fos alleles (Figure 5a and Supplementary Figure 5A) . No difference in tumour volume was observed in mice at one week of age (Supplementary Figure 5B) . However, at the age of 4 weeks the tumour volume was decreased to approximately 50% in the absence of Fos C-terminal phosphorylation (SOS þ FosAA, Figure 5b ). Histological analyses revealed no striking differences in the appearance or cellular composition (Supplementary Figure 5c) . These data indicate that impairing Fos phosphorylation on serines 362 and 374 significantly delayed but did not abolish skin tumourigenesis caused by dominant active SOS. Conversely, when crossed to phospho-mimetic Fos DD mice, the resulting double mutant mice (SOS þ FosDD) developed significantly larger papillomas (Figure 5c ) supporting the contribution of Fos Cterminal phosphorylation to SOS-induced papilloma development.
The relative contribution of each individual serine was investigated by crossing K5-SOS-F mice into Fos362A and Fos374A homozygote backgrounds. In contrast to what was observed in osteoclasts and macrophages, phosphorylation of Fos on serine 362 seems to have a dominant, if not exclusive role in skin tumourigenesis To further prove the contribution of serine 362 phosphorylation to skin papilloma development, mice lacking Rsk2 were used. A significant reduction in tumour volume was observed in K5-SOS-F mice in a Rsk2-deficient background (Figure 5e ). In the context of Fos-induced osteosarcomas, Rsk2 deletion results in decreased stability of un-phosphorylated, ectopicallyexpressed Fos protein . Interestingly, although Fos phosphorylation on serine 362 was undectable in Rsk2-deficient K5-SOS-F-expressing tumour sections, Fos protein remained detectable (Figure 5f and Supplementary Figure 5D ). This indicates that in K5-SOS-F-expressing epidermis, C-terminal phosphorylation of Fos, presumably by RSK2, has little impact on Fos stability, but may modulate instead Fos transcriptional activity on target genes critical for papilloma formation.
Fos phosphorylation differentially regulates Fos target gene expression
The epidermal growth factor receptor provides an essential survival signal to K5-SOS-F-induced papillomas (Sibilia et al., 2000) and c-Jun/AP-1 controls egfr transcription (Zenz et al., 2003) . Egfr mRNA levels were found unaffected in FosAA, Fos362A, FosDD and Rsk2-deficient papillomas (Supplementary Figure 5E ) indicating that egfr is likely not a transcriptional target of phosphorylated Fos in K5-SOS-Finduced papillomas. The Fos-related protein Fra1 is a bona fide Fos target gene and Fra1 can largely substitute for Fos in vivo . In addition, the C-terminal Fos phosphorylation sites are conserved in Fra1 and Fra1 might be a critical target of ERK1/2 and RSK1/2 kinases (Basbous et al., 2007; Casalino et al., 2007; Doehn et al., 2009; Shin et al., 2010) . Fra1 is readily detectable in K5-SOS-F-expressing wildtype, FosAA, FosDD and Rsk2-deficient papillomas (Supplementary Figure 5F ). Quantitative PCR analyses revealed a decrease of fra1 mRNA expression in FosAA and SOS þ Rsk-deficient tumours, which was mirrored by an increase in SOS þ FosDD tumours (Figure 6a ). To genetically address the contribution of Fra1 and the potential Fra1 phosphorylation by RSK2 to SOS-induced papilloma development, knock-in mice that expressed Fra1 in place of Fos were used (Fos Fra1 ). Immunohistochemical staining confirmed that Fos expression was lost in SOS þ Fos Fra1 tumours (Figure 6b) . A significant reduction in tumour volume was observed in K5-SOSF mice homozygous for the Fra1 knock-in allele (Figure 6c ). These data indicate that although Fra1 expression might be modulated by Fos C-terminal phosphorylation, it is very likely that it is not an essential downstream target of Fos and RSK2 and cannot substitute for Fos during skin papilloma development.
Global gene expression analyses using tumour samples from wild-type and epidermis-specific Fos-deficient K5-SOS-F mice revealed a number of genes whose expression was regulated by Fos (Durchdewald et al., 2008) . To gain more insights into the contribution of Fos phosphorylation to Fos target gene expression, mRNA expression of a subset of genes among the most differentially up-or down-regulated in the absence of Fos was examined in SOS þ FosAA and Fos DD tumours. Special attention was given to genes wherein experimental evidence supporting a direct transcriptional regulation by Fos, such as pdpn, klk12, mmp10, s100a3 and tgfbi were available ( (Durchdewald et al., 2008) and Wagner lab unpublished).
Most of the genes up-or down-regulated in the absence of Fos expression were similarly affected, when Fos-priming phosphorylation was impaired by the AA substitution (Figures 6d and e) . In addition, all previously identified Fos targets were inversely affected by the phosphomimetic FosDD substitution (Figures 6f  and g ). This indicates that Fos C-terminal phosphorylation is critical for the transcriptional activating or repressing function of Fos on these genes. The mRNA expression of Pdpn and klk12, however, was unaffected by single 362A or double alanine substitution or the lack of Rsk2, but enhanced by the phosphomimetic substitutions (Figures 6d and f and Supplementary Figure 5G ). This indicates that although phosphorylation might enhance Fos transactivation on the promoter of these genes, a Fos protein with the phosphorylation priming sites mutated to alanines is sufficient to promote pdpn and klk12 expression to levels comparable to controls. These data indicate that Fos C-terminal phosphorylation exerts a gene-dependent regulatory role on the Fosdependent transcriptional program downstream of the ras pathway during skin tumourigenesis.
Discussion
The analysis of mice lacking the c-fos gene has provided insights into its specific biological functions in development and tissue homeostasis, as well as in pathological conditions such as stress response and tumour formation. Post-translational modifications of the Fos protein and, in particular, phosphorylation of its extreme C-terminus have been described more than two decades ago (Curran et al., 1984; Barber and Verma, 1987 ) and postulated to be important to Fos pleiotropic functions in normal and pathological conditions. However, as most of the available evidence relied on overexpression experiments using cultured cell lines, a definitive genetic and in vivo proof for the relevance of Fos C-terminal phosphorylation in the context of physiological c-fos expression in the whole organism was lacking. We have generated phospho-knock-in Fos mice with the best in vitro-characterized phosphorylation sites substituted by alanines or aspartic acids in the endogenous Fos protein and examined Fos-related biological responses in vivo as well as in primary cell cultures. Although experiments with primary phospho-knock-in cells largely supported previous in vitro findings regarding the In vivo functions of Fos phosphorylation L Bakiri et al relevance of Fos phosphorylation during stress or growth factor response, our study provides the first genetic evidence for a regulatory role of Fos C-terminal phosphorylation in vivo and the first genetic demonstration that serine 362 and 374 are not functionally equivalent in vivo and in vitro.
Homozygous FosAA, FosDD, Fos362A and Fos374A mutant mice were indistinguishable from controls and skeletogenesis was largely unaffected. However, osteoclast differentiation in vitro and mRNA expression of Fos-target genes implicated in osteoclast differentiation, such as nfatc1 appeared sensitive to Fos C-terminal phosphorylation. This phenotype appeared predominantly dependent on serine 374 and supports our previous findings using mice lacking the putative serine 362 kinase Rsk2 . Osteoclastogenesis was largely rescued by co-culture with osteoblasts and bone resorption was unaffected in vivo indicating that Fos phosphorylation might only be relevant in osteoclasts under stress conditions.
The modulation of macrophage activation is important for homeostasis of the immune system as well as resolution of inflammation. Fos knock-out mice are more sensitive to acute inflammatory stress in response to LPS, an experimental paradigm for endotoxemia (Ray et al., 2006; Takada et al., 2010) . We genetically demonstrate that Fos C-terminal phosphorylation modulates acute inflammatory stress responses in vitro and in vivo. LPS activates Toll-like receptor signalling and leads to NF-kB and AP-1 activation. Whether Fos phosphorylation is involved in the recently identified interaction between Fos and p65 on the tnfa promoter (Koga et al., 2009) and whether a similar co-regulatory interaction applies to il6 and il10 transcription requires further investigation. Nevertheless, our data indicate that transiently enhancing Fos phosphorylation might represent a novel therapeutic principle for rapid suppression of endotoxin shock and inflammatory diseases.
To test the significance of Fos C-terminal phosphorylation as a target of Ras in vivo, we have chosen skin tumourigenesis as a model system. We found tumour formation by the K5-SOS-F transgene modulated by Fos C-terminal phosphorylation and identified an important role for serine 362 and its putative kinase RSK2 in this context. Few reports have addressed the relative contribution of each of the priming C-terminal serines to Fos function and it has been assumed that In vivo functions of Fos phosphorylation L Bakiri et al phosphorylation at both sites functions similarly to enhance Fos stability and transformation potential. Genetic evidence now proves that serine 362 is a major determinant of Fos function in the context of Rasmediated papilloma formation in vivo, which is in contrast to its minor role in cells of the monocyte/ macrophage lineage. Future experiments will certainly shed additional light on the relative contribution of each serine to other in vivo functions of Fos such as hippocampus-dependent learning and memory processes (Fleischmann et al., 2003a) . When analysing mRNA expression of a subset of Fosregulated genes in K5-SOS-F papillomas, Fos target genes could be segregated into two categories, depending on whether they required Fos C-terminal phosphorylation for proper mRNA expression. Most of the Fosrepressed genes were sensitive to C-terminal phosphorylation. Interestingly, the priming-phosphorylation sites are located in a region of Fos that has been termed trans-repression domain, because it was essential for Fos-mediated repression of its own expression and that of other immediate early genes (Sassone-Corsi et al., 1988; Gius et al., 1990; Ofir et al., 1990) . We observed alterations in c-fos and egr-1 serum-induced expression in FosAA and FosDD fibroblasts, which confirm early reports and provide further genetic proof to the transcriptional negative feedback loop operating at the c-fos promoter. Recently, an elegant combination of mathematical modelling and experiments has modelled 'the Fos system' and postulated that an increase in the negative feedback loop operated by both dual-specificity ERK phosphatases and an unknown Fos transcriptional repressor would result in a more robust cumulative Fos response (Nakakuki et al., 2010) . It is tempting to speculate that phosphorylated Fos, exemplified by FosDD in our genetic model, might represent the unknown Fos transcriptional repressor participating in the modulation of the Fos response.
The priming-phosphorylation sites are largely conserved in other Fos proteins and the functionality of the Fra1 phosphorylation sites downstream of Ras have been demonstrated in cultured cells (Basbous et al., 2007; Doehn et al., 2009; Shin et al., 2010) . Despite this compelling evidence, Fra1 is unlikely an essential target of Ras during skin tumourigenesis as it cannot substitute for Fos in papilloma formation. Interestingly, Fra1 can take over most of Fos physiological functions when expressed from the c-fos locus . In particular, Fra1 compensates for the lack of Fos in bone development. As bone homeostasis is also largely unaffected by Fos C-terminal phosphorylation (this study and ), an attractive hypothesis is that Fos-and Fra1-containing dimers are more promiscuous in their transcriptional targets during bone development than during Ras-induced tumourigenesis. The essential Fos target-genes in bone cells are less sensitive to the identity of the Fos partner in the AP-1 dimer, in particular its phosphorylation on serine 362, than to overall Fos protein levels, provided that the Fos protein is expressed at the right time and place. Consistently, Fos-induced osteosarcoma development is significantly delayed, when Fos levels are reduced by knocking out a single endogenous c-fos allele or inactivating Rsk2 (Wang et al., 1995; David et al., 2005) .
An unexpected tumour-suppressor activity of Fos has been recently unravelled. The p53/c-fos double knockout mice developed orbital rhabdomyosarcoma, a tumour type rarely seen in p53-null mice (Fleischmann et al., 2003b) . FosAA mice bred into a p53-deficient background did not develop rhabdomyosarcoma (L Bakiri, unpublished data), indicating that a phosphorylation-mutant Fos protein is able to maintain the genetic program by which Fos suppresses muscle tumour formation. This further suggests that the functions of Fos C-terminal phosphorylation in Fosdependent tumourigenesis are gene-, cell-type-and cell context-dependent.
Comprehensive identification of the target genes that are exclusively controlled or shared by individual Fos/ AP-1 members in different contexts will certainly lead to a better understanding of AP-1 biological functions. However, it is very unlikely that a single Fos target gene can account for all of the Fos functions in a particular context. Therefore, targeting Fos and its immediate upstream regulators remain the best option to interfere with pathological processes. Because Fos phosphorylation does not seem to be required for vital physiological functions, it could represent an attractive alternative for the treatment of clinically relevant conditions such as inflammatory diseases and cancer.
Materials and methods
Gene targeting and generation of phospho-knock-in mice An Eco47III-NsiI fragment containing exons 1-4 of c-fos was excised from the floxed c-fos lox-targeting construct (Fleischmann et al., 2003a) and the 5 0 loxP site removed. The desired nucleotides substitutions were introduced using the Quickchange mutagenesis kit (Stratagene, Vienna, Austria) following the manufacturer's instructions. The mutagenized fragment was reintroduced in the floxed c-fos lox-targeting construct. HM1 embryonic stem cells were electroporated with each linearized knock-in construct and screened for homologous recombination. Several correctly targeted clones were identified by PCR and Southern analyses as described earlier (Fleischmann et al., 2003a) . The conversion of serine 374 to alanine or to aspartic acid led to the loss of a SacI site and was used as an additional screening method for correct targeting. Mouse chimeras were generated by injecting correctly targeted embryonic stem cell clones into C57/BL6 blastocysts and the neo cassette was deleted in vivo by crossing to a Flpe deleter line (Dymecki, 1996) . The Fos floxed (Fleischmann et al., 2003a) , Rsk2 KO (Yang et al., 2004) , Fos Fra , LysMcre (Clausen et al., 1999) and K5-SOS-F (Sibilia et al., 2000) mouse lines are described elsewhere. Mice were kept on a mixed (C57Bl/6 Â 129/Sv) or C57Bl/6 genetic background and sex-matching littermates were used as controls. All mouse experiments were performed in accordance with local and institutional regulations.
Histological analysis
Tissues were fixed in 4% formaldehyde, embedded in paraffin, 5 mm sectioned and stained either with haematoxylin and eosin
In vivo functions of Fos phosphorylation L Bakiri et al (Sigma, Vienna, Austria) or processed further. Immunohistochemical staining for Fos (Sigma), pSer362-Fos , Fra1 (Santa Cruz Biotechnologies, Vienna, Austria), keratin5 and Loricrin (Covance, Freiburg, Germany) was performed using EnVision DAB þ kit (Dako, Vienna, Austria). For histomorphometry, undecalcified tibiae were embedded in methylmethacrylate. Quantitative histomorphometry was performed in accordance with standardized protocols (Parfitt et al., 1987) using Osteomeasure (OsteoMetrics, Decatur, GA, USA).
Micro-computed tomography
Formalin fixed legs were scanned using an eXplore Locus micro computed tomography scanner (GE Healthcare, Madrid, Spain). A three-dimentional voxel model of the bone was built using MicroView (GE Healthcare) and volumetric bone and tissue mineral density were quantified as the mean of three consecutive slices, 1 mm below the growth plate of the right proximal tibia.
LPS-induced cytokine response
Mice were injected intraperitoneally with 4 mg/kg LPS (Sigma) and serum was collected 4-5 h later. Pure C57Bl/6 male littermates, 8-12 weeks old, were used to minimize for sex and background-variations.
Serum and culture supernatant measurements TNFa, IL-6, IL-10, OPG and receptor activator of NF-kB ligand were quantified using Quantikine ELISA Systems (R&D systems, Madrid, Spain). Serum Osteocalcin and carboxy-terminal collagen were quantified using commercially available ELISA systems (Biomedical Biomedica, Vienna, Austria and Nordic Bioscience, Herlev, Denmark, respectively). Whole blood alkaline phosphatase, calcium and phosphate were measured using VetScan (Abaxis, Barcelona, Spain) according to the manufacturer's instructions.
Primary cell cultures
Mouse embryonic fibroblasts were isolated from E12.5 foetuses and cultured in Dulbecco's modified Eagles medium (Sigma) containing 10% fetal calf serum. Cells were serumdeprived for 24 h and stimulated by adding serum to a final concentration of 20%. Osteoblasts were isolated from newborn calvariae and cultured in minimum essential mediuma (Sigma) containing 10% fetal calf serum and mineralization was assessed as previously described . Bone marrow cells were isolated from long bones and cultured with 10-50 ng/ml macrophage colony-stimulating factor (R&D). LPS (Sigma) was used at a final concentration of 0.1 and 1 ng/ml. Osteoclast differentiation in the presence of receptor activator of NF-kB ligand (R&D) or with osteoblasts was performed as previously described Bakiri et al., 2007) . All cell culture assays were performed at least twice with three replicates per experiment.
